技术平台
关键技术,全栈打通
-
Cell/Strain Construction and Banking -
CMC Development -
Drug Substance Manufacturing -
Formulation Development and ManufacturingFormulation Development and ManufacturingLearn more >>
服务范围
药物研发至生产全流程服务

R&D Services
- Molecular Construction
- Process Optimization & Process Characterization
- Small-scale Process Development
- Pilot Scale-up
- Pilot Scale-up
- Resin & Membrane Lifetime Assessment

Quality Service
- Quality Control
- Quality Management


Manufacturing Service
- Eukaryotic Drug Substance: 50L / 250L / 500L (ATF) / 2000L
- Prokaryotic Drug Substance: 100L / 50L+500L / 50L+250L+2000L
- Sterile Formulations: Injections, gels, ophthalmic preparations, inhalants

Regulatory Service
- IND
- CMC Regulatory Filing
- BLA / MAA
- China-US-EU Multi-region Filing
新闻资讯
发布最新消息,关注实时动态
-
Sep 27,2026Good News | Chuangrui Biotech Wins the Second Prize of 2026 Zhejiang New-field & New-quality Innovation Competition
-
Jul 30,2026Good News|Chuangrui Bio Supports Hengrui’s China-US Dual Filing Project, SHR-5421 for Injection Granted IND Approval
-
May 06,2024Liu Zhiyi, Second-level Inspector of Zhejiang Provincial Federation of Industry and Commerce, and his entourage visited Chuangrui Bio for investigation and research.
-
Apr 30,2024Moving Forward Hand in Hand|Chuangrui Bio and Weipu Bio Hold Strategic Cooperation Signing Ceremony — Highlights of the Biopharmaceutical Technology Exchange Salon

